## **Core Concept**
Eales' disease is a rare ophthalmic disorder characterized by recurrent retinal and vitreous hemorrhages, retinal ischemia, and neovascularization. It primarily affects young adults. The condition is thought to result from an abnormal immune response and is associated with **tuberculin hypersensitivity** and **allergic vasculitis**.

## **Why the Correct Answer is Right**
The correct treatment for Eales' disease involves addressing the underlying inflammation and neovascularization. **Corticosteroids** and ** immunosuppressive agents** are often used to control inflammation. However, the most specific and effective treatment listed for Eales' disease involves **photocoagulation** (or laser therapy) to reduce neovascularization and prevent further hemorrhages. Among the options provided, Anti-vascular endothelial growth factor (anti-VEGF) therapy is also considered, but the best-established treatment is actually **laser photocoagulation**.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although intravitreal anti-VEGF injections can be used off-label for neovascularization in Eales' disease, they are not considered the first-line treatment.
- **Option B:** This option is incorrect as there is no widely recognized treatment for Eales' disease specifically termed as "observation."
- **Option D:** This option is incorrect because, while vitrectomy may be necessary in some cases of severe vitreous hemorrhage or retinal detachment secondary to Eales' disease, it is not the primary treatment for the disease process itself.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that Eales' disease often requires **screening for tuberculosis** due to its association with tuberculin hypersensitivity. Additionally, patients with Eales' disease should be monitored closely for signs of **retinal neovascularization** and **vitreous hemorrhage**, as these are common complications.

## **Correct Answer Line**
**Correct Answer: C.**